High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

• Published in: International journal of cancer 2010-07, Vol.127 (1), p.138-147
• Main Authors: He, Li‐Ru, Liu, Meng‐Zhong, Li, Bin‐Kui, Jia, Wei‐Hua, Zhang, Ying, Liao, Yi‐Ji, Chen, Yang‐Chao, Zhang, Lan‐Jun, Guan, Xin‐Yuan, Zeng, Yi‐Xin, Kung, Hsiang‐Fu, Xie, Dan
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - radiotherapy; Cell Proliferation; chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins - genetics; Enhancer of Zeste Homolog 2 Protein; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - genetics; Esophageal Neoplasms - pathology; Esophageal Neoplasms - radiotherapy; esophageal squamous cell carcinoma; Esophagus; EZH2; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Medical sciences; Middle Aged; Polycomb Repressive Complex 2; Prognosis; Transcription Factors - genetics; Tumors
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.25031

The enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, the methods of immunohistochemistry and fluorescence in‐situ hybridization were used to examine protein expression and amplification of EZH2 in 98 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (CRT). High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively. High EZH2 expression was significantly correlated with increased cell proliferation (p = 0.009), high histopathological grade (p = 0.002), regional (p = 0.025) and distant lymph node metastasis (p < 0.001) and lack of clinical complete response to CRT (p = 0.028). Univariate analysis revealed that high expression of EZH2 was associated with poor metastasis‐free survival (MFS) (p = 0.003), poor progression‐free survival (PFS) (p = 0.001) and poor disease‐specific survival (DSS) (p < 0.001). In multivariate analysis, high expression of EZH2, together with lack of clinical complete response, were evaluated as significant independent prognostic factors of MFS, PFS and DSS for patients with ESCC. These findings suggest that high expression of EZH2 correlates with tumor aggressiveness and adverse patient outcome in ESCC treated with definitive CRT. Evaluation of EZH2 expressions might be useful for predicting tumor response to CRT and prognosis for patients with ESCC.